Have a feature idea you'd love to see implemented?
Let us know!
ALVR Allovir Inc
Price (delayed)
$0.7685
Market cap
$88.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
-$7.63M
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative
Highlights
The quick ratio has soared by 199% since the previous quarter
Allovir's debt has plunged by 71% YoY and by 51% from the previous quarter
The equity has declined by 47% year-on-year
Key stats
What are the main financial stats of ALVR
Market
Valuations
Earnings
Shares outstanding
115.37M
Market cap
$88.66M
Enterprise value
-$7.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.73
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$140.47M
EBITDA
-$132.44M
Free cash flow
-$120.91M
Per share
Balance sheet
Liquidity
EPS
-$1.23
Free cash flow per share
-$1.05
Book value per share
$1.05
Revenue per share
$0
TBVPS
$1.14
Total assets
$130.99M
Total liabilities
$10.7M
Debt
$9M
Equity
$120.29M
Working capital
$127.58M
Debt to equity
0.07
Current ratio
55.08
Quick ratio
55.18
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-78.6%
Return on equity
-96.5%
Return on invested capital
-160%
Return on capital employed
-109.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALVR stock price
How has the Allovir stock price performed over time
Intraday
-1.17%
1 week
-4%
1 month
-1.34%
1 year
-46.26%
YTD
13.05%
QTD
-4.95%
Financial performance
How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$149.44M
Net income
-$140.34M
Gross margin
N/A
Net margin
N/A
The net income is up by 22% since the previous quarter and by 16% year-on-year
The operating income has grown by 21% from the previous quarter and by 14% YoY
Growth
What is Allovir's growth rate over time
Valuation
What is Allovir stock price valuation
P/E
N/A
P/B
0.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 31% YoY and by 26% QoQ
The price to book (P/B) is 74% less than the 5-year quarterly average of 2.9 and 8% less than the last 4 quarters average of 0.8
The equity has declined by 47% year-on-year
Efficiency
How efficient is Allovir business performance
Allovir's return on invested capital has decreased by 37% YoY but it has increased by 10% QoQ
ALVR's return on equity is down by 30% year-on-year but it is up by 7% since the previous quarter
The return on assets has declined by 29% year-on-year but it rose by 5% since the previous quarter
Dividends
What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALVR.
Financial health
How did Allovir financials performed over time
The quick ratio has soared by 199% since the previous quarter
The current ratio has soared by 198% from the previous quarter
Allovir's debt is 93% less than its equity
Allovir's debt has plunged by 71% YoY and by 51% from the previous quarter
ALVR's debt to equity has dropped by 53% since the previous quarter and by 50% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.